| Literature DB >> 36157636 |
You-Wei Li1, Yang Jiao2, Na Chen3, Qiang Gao4, Yu-Kun Chen1, Yuan-Fang Zhang1, Qi-Ping Wen1, Zong-Ming Zhang5.
Abstract
BACKGROUND: Early quantitative assessment of liver fat content is essential for patients with fatty liver disease. Mounting evidence has shown that magnetic resonance (MR) technique has high accuracy in the quantitative analysis of fatty liver, and is suitable for monitoring the therapeutic effect on fatty liver. However, many packaging methods and postprocessing functions have puzzled radiologists in clinical applications. Therefore, selecting a quantitative MR imaging technique for patients with fatty liver disease remains challenging. AIM: To provide information for the proper selection of commonly used quantitative MR techniques to quantify fatty liver.Entities:
Keywords: 1H-magnetic resonance spectroscopy; Fatty liver; Hepatic fat content; Multiple-point Dixon imaging; Two-point Dixon imaging
Year: 2022 PMID: 36157636 PMCID: PMC9477046 DOI: 10.12998/wjcc.v10.i25.8906
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1Flowchart of the study selection. MR: Magnetic resonance.
Studies reporting on the measurement of the hepatic fat content with 1H-magnetic resonance spectroscopy versus liver biopsy and other imaging methods
|
|
|
|
|
|
|
|
|
|
|
| Thomsen | 1994 | 48 | 14 | Fatty liver | 1.5 T. STEAM (TE = 34 ms) | Liver biopsy |
| ||
| Longo | 1995 | 45 | 29 | Diffuse steatosis | 1.5 T. PRESS (TE = 50–200 ms) | Liver biopsy |
| ||
| Cowin | 2008 | 42 | 12 | Steatosis | 1.5 T. PRESS (TE = 30 ms) | Liver biopsy | 6 wk |
| |
| Irwan | 2008 | Prospective | 47 | 10 | Healthy volunteers | 1.5 T. PRESS (TE = 30 ms) | Dual-echo imaging | One measurement session |
|
| Kim | 2008 | Prospective | 15.9 ± 5.3 | 28 | Lean and obese | 1.5 TPRESS (TE = 20 ms) | Two-Point Dixon |
| |
| Borra | 2009 | Prospective | 62.8 ± 8.3 | 33 | Type 2 diabetes | 1.5 T. PRESS (TE = 25 ms) | IP/OP (Dixon) |
| |
| Reeder | 2009 | Prospective | 49.0 ± 12 | 31 | Suspected steatosis and unrelated reasons | 1.5 T. PRESS (TE = 25 ms) | IDEAL |
| |
| Zhong | 2009 | 50 ± 12 | 36 | Fatty liver | 3.0 T. PRESS (TE = 144 ms) | 16-row multislice CT |
| ||
| Hu | 2010 | 16 | 3.0 T. PRESS (TE = 23 ms) | IDEAL | Slope = 0.90, intercept = 1.07%; | ||||
| Roldan-Valadez | 2010 | 35 | 18 | Steatosis | 3.0 T | Liver biopsy |
| ||
| Mehta | 2010 | 39.9 | 50 | Steatosis | 1.5 T. PRESS (TE = 135 ms) | Ultrasound | BMI > 30, sensitivity 96%; BMI ≤ 30, sensitivity 64% | ||
| Meisamy | 2011 | Prospective | 40 | 55 | 1.5 T. STEAM (TE = 10, 20, 30, 40, and 50 ms) | IDEAL |
| ||
| Georgoff | 2012 | Prospective | 50.6 | 52 | Steatosis | 3.0 T. PRESS (TE = 50 ms) | Liver biopsy | 15 ± 9 d | Diagnostic accuracy was (AUC: 0.95; 95%CI: 0.89–1.0) |
| Kang | 2012 | Prospective | 54 | 56 | Steatosis | 1.5 T. STEAM (TE = 20, 30, 40, 50, and 60 ms) | Liver biopsy | 1–28 d |
|
| Parente | 2014 | Prospective | 54 ± 9 | 73 | Nonalcoholic fatty liver disease | 3.0 T. PRESS (TE = 40 ms) | Liver biopsy |
| |
| Bashir | 2015 | Prospective | 55 ± 13.8 | 217 | Various hepatic diseases | 1.5 T. STEAM (TE = 12 ms) | Two-point Dixon |
| |
| Kim | 2015 | 52.8 ± 14 | 42 | Various hepatic diseases | 3.0 T. STEAM (TE = 12, 24, 36, 48, and 72 ms) | In- and opposed-phase echo pairs |
| ||
| Satkunasingham | 2015 | Retrospective | 57.8 (12–83) | 156 | Various hepatic diseases | 3.0 T. STEAM (TE = 12, 24, 36, 48, and 72 ms) | MRI-PDFF |
| |
| Rastogi | 2016 | Retrospective | 32.5 | 73 | Steatosis | 3.0 T. STEAM (TE = 15, 20, 25, 30, and 35 ms) | Biopsy and surgery | ≤ 20 d | MRS correlated well with the histopathology results ( |
| Kramer | 2017 | Prospective | 57 ± 5 | 50 | Various hepatic diseases | 1.5 T. STEAM (TE = 10, 20, 30, 40, and 50 ms) | PDFF |
|
MRS: Magnetic resonance spectroscopy; PDFF: Proton density fat fraction; TE: Echo time; BMI: Body mass index; CT: Computed tomography; Blank: No information; PRESS: Point-resolved spectroscopy; STEAM: Stimulated-echo acquisition mode.
Studies reporting on the measurement of the hepatic fat content with multiple-point Dixon imaging versus liver biopsy and other imaging methods
|
|
|
|
|
|
|
|
|
|
|
| Noureddin | 2013 | Randomized | 50 | Nonalcoholic fatty liver disease | MRI-PDFF | MRS | 0 and 24 wk |
| |
| Idilman | 2013 | Prospective | 44.7 ± 13.1 | 70 | Nonalcoholic fatty liver disease | 1.5 T. IDEAL-IQ | Biopsy | 14.5 d (0–259) |
|
| Deng | 2014 | Prospective | 3–16 | 10 | Nonalcoholic fatty liver disease | 1.5 T. Multi-point Dixon | Biopsy |
| |
| Kukuk | 2015 | 51.7 ± 15.2 | 59 | Liver disorders | 3.0 T. Six echo-mDixon | Biopsy | ≤ 6 wk |
| |
| Rehm | 2015 | Prospective | 13.3 ± 2 (11–22) | 132 | Healthy females | 3.0 T. Multi-echo Dixon | STEAM (TE = 10, 15, 20, 25, and 30 ms) |
| |
| Schwimmer | 2015 | Prospective | 14 | 174 | No steatosis and nonalcoholic fatty liver disease | 3.0 T. Multi-echo Dixon | Biopsy | 57 ± 51 d |
|
| Idilman | 2016 | Retrospective | 41.7 ± 14.6 | 19 | Nonalcoholic fatty liver disease | 1.5 T. DEAL-IQ | Biopsy |
| |
| Hetterich | 2016 | Prospective | 57.2 ± 9.4 | 215 | 3.0 T. STEAM (TE = 12, 24, 36, 48, and 72 ms) | Multi-echo Dixon |
| ||
| Middleton | 2017 | Randomized | 51 ± 11 | 113 | Nonalcoholic steatohepatitis | 1.5 T or 3.0 T. Six echo-mDixon | Biopsy | 51 d |
|
| Kang | 2018 | Prospective | 47.3 ± 14.9 | 29 | NAFLD (34). Alcoholic liver disease (13). Liver cirrhosis (9) | 3.0 T. mDIXON-Quant sequence | Biopsy | Same day |
|
| Pickhardt | 2018 | Retrospective | 54 ± 12 | 221 | 1.5 T or 3.0 T. MRI-PDFF | CT | 0–158 mo |
| |
| Guo | 2020 | PProspective | 52.6 (22–83) | 400 | Healthy adults and older adults | 3.0 T mDixon-Quant sequence | CT | Same day |
|
MRS: Magnetic resonance spectroscopy; PDFF: Proton density fat fraction; TE: Echo time; BMI: Body mass index; CT: Computed tomography; Blank: No information; PRESS: Point-resolved spectroscopy; STEAM: Stimulated-echo acquisition mode.
Figure 2Risk-of-bias and applicability concerns graph. A: Studies for 1H-magnetic resonance spectroscopy vs liver biology and other imaging methods in measuring hepatic fat content; B: Studies for in-phase and out-of-phase imaging vs liver biology and other imaging methods in measuring hepatic fat content; C: Studies for multiple-point Dixon imaging vs liver biology and other imaging methods in measuring hepatic fat content.
Studies reporting on the measurement of the hepatic fat content with in-phase and out-of-phase imaging versus liver biopsy and other imaging methods
|
|
|
|
|
|
|
|
|
|
|
| Fishbein e | 2005 | 47 ± 10 | 38 | Various hepatic diseases | 1.5 T. IP/OP (Dixon) | Biopsy | 2 wk |
| |
| Kalra | 2009 | Prospective | 41 ± 9.2 | 10 | Nonalcoholic fatty liver disease | 1.5 T. IP/OP (Dixon) | Biopsy | Provides data on fat infiltration without information of hepatic fibrosis | |
| Mennesson | 2009 | Prospective | 52.5 | 40 | Various hepatic diseases | 1.5 T. IP/OP (Dixon) | Biopsy | Same day |
|
| Fischer | 2010 | Prospective | 66 ± 12 | 23 | Various hepatic diseases | 1.5 T IP/OP (Dixon) | Biopsy and surgery | ≤ 10 d |
|
| Pacifico | 2011 | Case–control | 7-16 | 25 | Nonalcoholicfatty liver disease | 1.5 T. Two-point Dixon | Biopsy | 1–7 d |
|
| Guaraldi | 2012 | Observational pilot | 16 | 1.5 T. IP/OP (Dixon) | Biopsy |
| |||
| Koelblinger | 2012 | Prospective | 60.5 | 35 | Various hepatic diseases | 3.0 T. IP/OP (Dixon) | Biopsy | Uncorrected: | |
| Rastogi | 2016 | Retrospective | 32.5 | 73 | Steatosis | 3.0 T. IP/OP (Dixon) | Biopsy and surgery | ≤ 20 d | Dual-echo MRI correlated well with the histopathology results ( |
| Bhat | 2017 | Prospective | 46 | 30 | Steatosis | 1.5 T. Two-point DIXON | Biopsy | 1 wk | Good correlation between the MR estimation of liver fat and histological grading. 90% of patients had a fat content of less than 10%. The maximal fat content of 28% was observed in one patient |
MRI: Magnetic resonance imaging; Blank: No information.